News for Gilead Sciences, Inc. - Google Finance

Hedge Funds Are Betting On Gilead Sciences, Inc. (GILD)

Thu, 23 May 2013 19:59:32 GMT

Hedge Funds Are Betting On Gilead Sciences, Inc. (GILD)
Insider Monkey (blog) - May 23, 2013

Is Gilead Sciences, Inc. (NASDAQ:GILD) undervalued? Prominent investors are becoming more confident. The number of bullish hedge fund bets moved up by 10 lately.

Johnson & Johnson (JNJ), Gilead Sciences, Inc. (GILD), AbbVie Inc (ABBV ...

Wed, 22 May 2013 17:19:16 GMT

Johnson & Johnson (JNJ), Gilead Sciences, Inc. (GILD), AbbVie Inc (ABBV ...
Insider Monkey (blog) - May 22, 2013

Johnson & Johnson (NYSE:JNJ)'s hepatitis C drug, simeprevir, recently received Priority Review status from the FDA. It was a surprising validation for Johnson & Johnson (NYSE:JNJ)'s mid-stage project.

Wickedly Overbought: Gilead, Johnson & Johnson, and PepsiCo Under the ... - SmallCap Network

GILEAD SCIENCES, INC. : European Medicines Agency Validates Gilead's ...

Tue, 21 May 2013 20:38:24 GMT

GILEAD SCIENCES, INC. : European Medicines Agency Validates Gilead's ...
4-traders (press release) - May 21, 2013

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Marketing Authorisation Application (MAA) for sofosbuvir, a once-daily oral nucleotide analogue inhibitor for the treatment of chronic hepatitis C virus (HCV) infection, which was ...

GILEAD SCIENCES, INC. : Gilead Hepatitis C Drug Gets Accelerated Review

Tue, 21 May 2013 21:51:35 GMT

GILEAD SCIENCES, INC. : Gilead Hepatitis C Drug Gets Accelerated Review
4-traders (press release) - May 21, 2013

Gilead Sciences Inc. (GILD) said the marketing authorization application for its new hepatitis C drug has been validated by the European Medicines Agency and granted accelerated assessment.

GILEAD SCIENCES, INC. : Gilead Announces Response Data from Phase 2 ...

Wed, 15 May 2013 22:36:38 GMT

GILEAD SCIENCES, INC. : Gilead Announces Response Data from Phase 2 ...
4-traders (press release) - May 15, 2013

Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from a Phase 2 study (Study 101-08) evaluating idelalisib (formerly GS-1101), an investigational, targeted, oral inhibitor of PI3K delta, in combination with rituximab for older patients with ...

Pipeline Progress at Gilead - Zacks.com
Experimental Gilead drug effective in early-stage leukemia trial - Reuters India

GILEAD SCIENCES, INC. : Gilead Sciences to Present at the 2013 UBS Global ...

Fri, 17 May 2013 20:11:35 GMT

GILEAD SCIENCES, INC. : Gilead Sciences to Present at the 2013 UBS Global ...
4-traders (press release) - May 17, 2013

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its corporate presentation will be webcast from the 2013 UBS Global Healthcare Conference in New York.

Gilead Sciences PT Raised to $67.00 at UBS AG (GILD) - The Utah People's Post

Gilead Sciences, Inc. (GILD) Call Traders Target New Highs

Tue, 14 May 2013 13:20:34 GMT

Gilead Sciences, Inc. (GILD) Call Traders Target New Highs
Schaeffers Research - May 14, 2013

Calls were the options of choice on Gilead Sciences, Inc. (NASDAQ:GILD) yesterday, with roughly 27,000 contracts crossing the tape during the course of the session.

News Behind Insider Trading: American International Group, First Solar, Gilead ...

Tue, 21 May 2013 12:55:43 GMT

News Behind Insider Trading: American International Group, First Solar, Gilead ...
MarketWatch (press release) - May 21, 2013

Gilead Sciences, Inc. (NASDAQ:GILD) : By the end of last trading session, Gilead Sciences (NASDAQ:GILD) dropped US$0.56 (or 0.99%) to US$55.74 with about 9.50 million shares exchanged hands for the session, compared to its average volume of 13.47 ...

Gilead Sciences, Inc. (NASDAQ:GILD) Investor Alert: Investigation over ... - SBWire (press release)
Gilead Sciences Price Target Raised to $67.00 at UBS AG (GILD) - Daily Political

Gilead Sciences To Present At UBS Global Conference; Webcast At 9:30 AM ET

Mon, 20 May 2013 11:33:54 GMT

Gilead Sciences To Present At UBS Global Conference; Webcast At 9:30 AM ET
NASDAQ - May 20, 2013

loading. (RTTNews.com) - Gilead Sciences Inc. ( GILD ) will present at the 2013 UBS Global Healthcare Conference in ,New York City .

Gilead Sciences Reports Higher Sales, FDA Letter

Thu, 02 May 2013 22:39:17 GMT

Gilead Sciences Reports Higher Sales, FDA Letter
Wall Street Journal - May 2, 2013

Gilead Sciences Inc.'s (GILD) first-quarter sales rose a disappointing 8.4% as increased traction for the newer additions to the company's HIV franchise wasn't enough to offset customers stocking up on its antiviral drugs ahead of price increases ...

GILEAD SCIENCES, INC. : Gilead Sciences Announces First Quarter 2013 ... - 4-traders (press release)
Gilead Sciences Inc. (GILD) Has Climbed To A New High On Q1 Results - RTT News